XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer

This study is testing a drug called XL092 (zanzalintinib) for people with advanced thyroid cancer that is no longer responding to radioactive iodine (RAI) — the standard treatment for differentiated thyroid cancer. The drug works by blocking signals that help tumors grow and form new blood vessels. **You may be eligible if...** - You have been diagnosed with locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hurthle cell, or poorly differentiated) - Your cancer no longer absorbs radioactive iodine (RAI-refractory), confirmed by specific scan criteria - Your cancer has progressed within the past 12 months - You have not previously received systemic treatment for RAI-refractory disease - Your overall health is adequate (ECOG 0–1) **You may NOT be eligible if...** - You have anaplastic thyroid cancer (a different, more aggressive type) - You have previously received a targeted therapy for this cancer (such as lenvatinib or sorafenib) - You have active heart disease or uncontrolled high blood pressure - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.